6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis

Drug Category: Array
Conference Category: Array
Lead Author: Fox E, et al.
Published Date: 01/02/2018
Download Link: /wp-content/uploads/2019/03/2018-ACTRIMS-Ublituximab-Poster.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top